secwatch.observer — SEC 8-K summary
======================================

Issuer:     Matinas BioPharma Holdings, Inc. (MTNB)
CIK:        0001582554
Form:       8-K
Filed at:   2024-03-27T23:59:59+00:00
Accession:  0001493152-24-011509
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Matinas BioPharma reports 2023 net loss $22.9M; cash runway only through Q3 2024
--------------------------------------------------------------------------------

- Revenue fell to $1.1M from $3.2M; net loss per share $0.11 vs $0.10 prior year.
- Cash and equivalents $13.8M at Dec 31, 2023, down from $28.8M; company sees funding only through Q3 2024.
- FDA agreed on design of single Phase 3 ORALTO trial for MAT2203 in invasive aspergillosis.
- Compassionate use program: 19 patients enrolled; most with renal recovery after switching from AmBisome; 8 completed with complete resolution.
- Preclinical LNC-docetaxel shows comparable efficacy to IV-docetaxel with no weight loss in mice.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1582554/000149315224011509/0001493152-24-011509-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1582554/000149315224011509/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-011509

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer